The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...